March 01, 2023 — 08:11 am EST

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - Oragenics, Inc. (OGEN) has entered into a license agreement with Inspirevax Inc. for its intranasal mucosal adjuvant, BDX301, for the development of NT-CoV2-1, the company's lead intranasal COVID-19 vaccine candidate. Oragenics will pursue the development of NT-CoV2-1 with Inspirevax's BDX301 intranasal mucosal adjuvant. Oragenics will make clinical, regulatory and commercial milestone payments, as well as tiered royalty payments. 
Kimberly Murphy, CEO of Oragenics, said: "There is an unmet medical need for an 
intranasal COVID-19 vaccine. We are currently evaluating formulation options for NT-CoV2-1 and assessing various regulatory pathways to advance this program efficiently and thoughtfully. We are working diligently to advance the program and intend to provide an update in mid-2023."
For More Such Health News, visit rttnews.com. 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.